Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
Abstract No approved therapy exists for cancer‐associated cachexia. The colon‐26 mouse model of cancer cachexia mimics recent late‐stage clinical failures of anabolic anti‐cachexia therapy and was unresponsive to anabolic doses of diverse androgens, including the selective androgen receptor modulato...
Saved in:
| Main Authors: | Sophia G Liva, Yu‐Chou Tseng, Anees M Dauki, Michael G Sovic, Trang Vu, Sally E Henderson, Yi‐Chiu Kuo, Jason A Benedict, Xiaoli Zhang, Bryan C Remaily, Samuel K Kulp, Moray Campbell, Tanios Bekaii‐Saab, Mitchell A Phelps, Ching‐Shih Chen, Christopher C Coss |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2020-01-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.201809910 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
DRUG THERAPY FOR ANDROGEN-POSITIVE BREAST CANCER
by: A. D. Zikiryakhodjhaev, et al.
Published: (2021-03-01) -
Androgens as the “old age stick” in skeletal muscle
by: Giulia Gentile, et al.
Published: (2025-04-01) -
Evaluation of implementing drug checking services for anabolic androgenic steroids in Switzerland: a pilot study
by: Raphael Magnolini, et al.
Published: (2025-06-01) -
Divergent androgen regulation of unfolded protein response pathways drives prostate cancer
by: Xia Sheng, et al.
Published: (2015-04-01) -
Cachexia index as a biomarker for cancer cachexia and quality of life in patients with gastric cancer
by: Yan Huang, et al.
Published: (2025-08-01)